{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:56Z","timestamp":1793237696937,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacadv.2026.103039","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:04:36Z","timestamp":1787774676000},"page":"103039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated Lipoprotein(a) Is Highly Prevalent in Autoimmune or Inflammatory Disease"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-0745","authenticated-orcid":false,"given":"Rebecca","family":"Ocher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0666-8461","authenticated-orcid":false,"given":"Mattheus","family":"Ramsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehtisham","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam R.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.103039_bib1","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data","volume":"135","author":"Abend","year":"2024","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.jacadv.2026.103039_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103039_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11883-024-01221-7","article-title":"The emerging specialty of cardio-rheumatology","volume":"26","author":"Nayfeh","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacadv.2026.103039_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ijwd.2021.08.015","article-title":"Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis","volume":"7","author":"Keyes","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jacadv.2026.103039_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ph15010011","article-title":"Treatment of cardiovascular disease in rheumatoid arthritis: a complex challenge with increased atherosclerotic risk","volume":"15","author":"Ahmed","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacadv.2026.103039_bib6","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacadv.2026.103039_bib7","doi-asserted-by":"crossref","first-page":"12906","DOI":"10.3390\/ijms232112906","article-title":"The role of inflammation in cardiovascular disease","volume":"23","author":"Henein","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"ec","key":"10.1016\/j.jacadv.2026.103039_bib8","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.ATV.0000174800.78362.ec","article-title":"Atherosclerosis in patients with autoimmune disorders","volume":"25","author":"Frostegard","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2026.103039_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1573403X13666170426104611","article-title":"The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature","volume":"13","author":"Diamantis","year":"2017","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jacadv.2026.103039_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacadv.2026.103039_bib11","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103039_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103039_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103039_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond Lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacadv.2026.103039_bib15","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/ATVBAHA.124.319983","article-title":"Immune-mediated inflammatory diseases, dyslipidemia, and cardiovascular risk: a complex interplay","volume":"44","author":"Wilkinson","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2026.103039_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119244","article-title":"Association of Lipoprotein(a) with cardiovascular events among individuals with autoimmune conditions","volume":"406","author":"Alebna","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2026.103039_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5603\/CJ.a2018.0106","article-title":"Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome","volume":"26","author":"Jubran","year":"2019","journal-title":"Cardiol J"},{"key":"10.1016\/j.jacadv.2026.103039_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103039_bib29","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacadv.2026.103039_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jacl.2017.02.018","article-title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project","volume":"11","author":"Garcia-Gomez","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacadv.2026.103039_bib19","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.4103\/0975-7406.155767","article-title":"A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects","volume":"7","author":"Govindan","year":"2015","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.jacadv.2026.103039_bib21","first-page":"220","article-title":"Lipoprotein(a) levels in systemic lupus erythematosus","volume":"21","author":"Borba","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacadv.2026.103039_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/480784","article-title":"A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jacadv.2026.103039_bib23","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/s41598-025-88375-9","article-title":"Mendelian randomization analysis does not support a causal influence between lipoprotein(A) and immune-mediated inflammatory diseases","volume":"15","author":"Ti","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2026.103039_bib24","first-page":"774","article-title":"Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in rheumatology (CARMA) project","volume":"37","author":"Garcia-Gomez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.103039_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey 2007\u20132016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacadv.2026.103039_bib26","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/clc.20511","article-title":"Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile","volume":"33","author":"Lippi","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacadv.2026.103039_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/ard.54.2.90","article-title":"Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout","volume":"54","author":"Takahashi","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacadv.2026.103039_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jacl.2010.08.021","article-title":"Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease","volume":"4","author":"Sappati Biyyani","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacadv.2026.103039_bib28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/00042737-200112000-00004","article-title":"Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?","volume":"13","author":"Koutroubakis","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacadv.2026.103039_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102205","article-title":"Lipoprotein(a) testing trends in the United States 2015-2024: an analysis of 300 million individuals","volume":"4","author":"Ramsis","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacadv.2026.103039_bib31","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacadv.2026.103039_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2026.103039_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cca.2007.12.015","article-title":"Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation","volume":"390","author":"Wang","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacadv.2026.103039_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower Lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2026.103039_bib36","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103039_bib37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacadv.2026.103039_bib38","article-title":"A systems immunology perspective on gout pathogenesis and its precision-targeted treatment strategies","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.103039_bib39","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.semarthrit.2020.06.015","article-title":"Advances in our understanding of gout as an auto-inflammatory disease","volume":"50","author":"Bodofsky","year":"2020","journal-title":"Semin Arthritis Rheum"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26004606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:28:01Z","timestamp":1793237281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26004606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2772963X26004606"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103039","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated Lipoprotein(a) Is Highly Prevalent in Autoimmune or Inflammatory Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103039"}}